Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
Exelon Pharmaceuticals
|
| gptkbp:CEO |
Jonathan Ross Goodman
|
| gptkbp:country |
gptkb:Canada
|
| gptkbp:focusesOn |
specialty pharmaceuticals
|
| gptkbp:foundedYear |
2014
|
| gptkbp:headquartersLocation |
Montreal, Quebec, Canada
|
| https://www.w3.org/2000/01/rdf-schema#label |
Knight Therapeutics
|
| gptkbp:industry |
pharmaceuticals
|
| gptkbp:notableProduct |
gptkb:Impavido
gptkb:Movantik Probuphine |
| gptkbp:publiclyTraded |
true
|
| gptkbp:regionServed |
gptkb:Canada
gptkb:Israel gptkb:Latin_America |
| gptkbp:stockExchange |
gptkb:Toronto_Stock_Exchange
|
| gptkbp:stockSymbol |
gptkb:GUD
|
| gptkbp:website |
https://www.gud-knight.com/
|
| gptkbp:bfsParent |
gptkb:Grupo_Biotoscana
|
| gptkbp:bfsLayer |
7
|